Navigation Links
Grant to fund research into eradicating the leukemia stem cell
Date:7/14/2010

The leukemia stem cellthe root cause of all acute leukemias represents a small population of cells in patients that are difficult to eliminate with standard treatments available today. Though current chemotherapy can produce temporary remission in leukemia survivors, they remain at risk of experiencing a recurrence and dying from the disease. The one exception is the remarkable cure of a rare form of leukemia called acute promyelocytic leukemia (APL), which came about from combining differentiation therapy with chemotherapy, and was pioneered by the collaboration between scientists at the Samuel Waxman Cancer Research Foundation (SWCRF) and the Shanghai Institute of Hematology (SIH) in China in 1982.

Now, a three-year grant of $375,000 from the Emerald Foundation, Inc. will further expand the collaboration between researchers from the SWCRF and researchers at the SIH. The SWCRF/Emerald Foundation, Inc. Global Collaborative Grant will fund critical research to identify new and more powerful drugs that can restore normal differentiation and cell growth to leukemia stem cells.

"The Emerald Foundation, Inc. seized the opportunity to partner with the Samuel Waxman Cancer Research Foundation in order to develop a cure for cancer. We truly believe in SWCRF's collaborative Institute Without Walls, which is made up of internationally-recognized scientists," said Gloria Thakuria, the scientific program officer at the Emerald Foundation, Inc. "It is through the collaboration between foundations, as well as the collaborations between scientists around the world that we will discover a cure for this deadly disease."

Gwen Darien, the executive director of the Foundation, agreed. "Collaboration is a hallmark of the Waxman Foundation's 35-year history, and has helped lead the SWCRF to make significant breakthroughs in cancer research," said Darien. "We are truly excited about partnering with the Emerald Foundation, Inc. in this collaborative grant to improve the lives of patients and families worldwide."

The grant will fund the following research projects:

  • The development and testing of a compound extracted from medicinal herbs known as Oridonin and its derivatives to attack the leukemia stem cell in clinical trials.

  • The utilization of mass sequencing analyses to better understand the leukemia stem cell.

  • Identification of leukemia stem cells in acute myeloid leukemia for further research in disease progression and treatment response.

The Foundation's mission has long focused on supporting cancer research that offers patients minimally toxic treatments, said Samuel Waxman, M.D., the scientific director of the SWCRF. "Eradicating the leukemia stem cell is the next logical step to fulfilling the Foundation's mission and goal of improving the quality of life and care for cancer patients," he said.


'/>"/>

Contact: Jenny Song
jsong@waxmancancer.org
212-867-4502
Samuel Waxman Cancer Research Foundation
Source:Eurekalert

Related biology news :

1. LSUHSC awarded $2 million dollar grant to prevent pneumonia linked to immune deficiency
2. The Samuel Waxman Cancer Research Foundation awards $1.54 million in research grants for 2010-2011
3. MSU researchers awarded $9.1 million grant to battle malaria in Malawi
4. Dr. Jayne Fulkerson receives $3.2 million NIH grant
5. NSF grant will develop new online hub for biochemistry, molecular biology educators
6. CIMIT announces $3 million in medical research grants
7. NHLBI grants $1.47 million to study red blood cell transfusion storage times and bioactivity
8. University of Chicago Press book wins Grantham Prize
9. NYU Langone Medical Center receives $5.4 million NYSTEM grant for stem cell research
10. Team of UC scientists awarded $2 million NIH grant for better flu diagnoses
11. Major magnet grant to advance state-of-the-art in chemical analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... SANTA MONICA, Calif. , June 23, 2016  The Prostate Cancer ... to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of ... 77 institutions across 15 countries. Read More About the ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample ... the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
Breaking Biology Technology: